IONS Quote, Financials, Valuation and Earnings

Biogen, Inc. has a net margin of -82.06% compared to Ionis Pharmaceuticals, Inc.'s net margin of 19%. Ionis Pharmaceuticals, Inc.'s return on equity of -43.01% beat Biogen, Inc.'s return on equity of 9.36%.

Ionis Pharmaceuticals, Inc. has a consensus price target of $90.63, signalling upside risk potential of 18.73%. On the other hand Biogen, Inc. has an analysts' consensus of $191.03 which suggests that it could grow by 16.19%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Biogen, Inc., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Biogen, Inc..

Ionis Pharmaceuticals, Inc. has a beta of 0.278, which suggesting that the stock is 72.158% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.127, suggesting its less volatile than the S&P 500 by 87.301%.

Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals, Inc. quarterly revenues are $156.7M, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. Ionis Pharmaceuticals, Inc.'s net income of -$128.6M is lower than Biogen, Inc.'s net income of $466.5M. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Biogen, Inc.'s PE ratio is 14.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 13.00x versus 2.49x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cogent Biosciences, Inc. has a net margin of -82.06% compared to Ionis Pharmaceuticals, Inc.'s net margin of --. Ionis Pharmaceuticals, Inc.'s return on equity of -43.01% beat Cogent Biosciences, Inc.'s return on equity of -117.99%.

Ionis Pharmaceuticals, Inc. has a consensus price target of $90.63, signalling upside risk potential of 18.73%. On the other hand Cogent Biosciences, Inc. has an analysts' consensus of $50.25 which suggests that it could grow by 29.05%. Given that Cogent Biosciences, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Ionis Pharmaceuticals, Inc. has a beta of 0.278, which suggesting that the stock is 72.158% less volatile than S&P 500. In comparison Cogent Biosciences, Inc. has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.585%.

Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cogent Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Cogent Biosciences, Inc. pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals, Inc. quarterly revenues are $156.7M, which are larger than Cogent Biosciences, Inc. quarterly revenues of --. Ionis Pharmaceuticals, Inc.'s net income of -$128.6M is lower than Cogent Biosciences, Inc.'s net income of -$80.9M. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Cogent Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 13.00x versus 55.99x for Cogent Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -82.06% compared to Ionis Pharmaceuticals, Inc.'s net margin of 31.72%. Ionis Pharmaceuticals, Inc.'s return on equity of -43.01% beat Eli Lilly & Co.'s return on equity of 106.26%.

Ionis Pharmaceuticals, Inc. has a consensus price target of $90.63, signalling upside risk potential of 18.73%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,110.79 which suggests that it could grow by 6.97%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Ionis Pharmaceuticals, Inc. has a beta of 0.278, which suggesting that the stock is 72.158% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ionis Pharmaceuticals, Inc. quarterly revenues are $156.7M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Ionis Pharmaceuticals, Inc.'s net income of -$128.6M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 51.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 13.00x versus 15.93x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -82.06% compared to Ionis Pharmaceuticals, Inc.'s net margin of 21.32%. Ionis Pharmaceuticals, Inc.'s return on equity of -43.01% beat Pfizer Inc.'s return on equity of 10.84%.

Ionis Pharmaceuticals, Inc. has a consensus price target of $90.63, signalling upside risk potential of 18.73%. On the other hand Pfizer Inc. has an analysts' consensus of $28.66 which suggests that it could grow by 11.72%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Pfizer Inc..

Ionis Pharmaceuticals, Inc. has a beta of 0.278, which suggesting that the stock is 72.158% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.71% to investors and pays a quarterly dividend of $0.43 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Ionis Pharmaceuticals, Inc. quarterly revenues are $156.7M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Ionis Pharmaceuticals, Inc.'s net income of -$128.6M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 13.00x versus 2.33x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.